We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

154 hedge funds and large institutions have $1.96B invested in Xenon Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 41

21% more capital invested

Capital invested by funds: $1.62B → $1.96B (+$345M)

13% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 23

13% more funds holding in top 10

Funds holding in top 10: 8 → 9 (+1)

2% more funds holding

Funds holding: 151 → 154 (+3)

0.13% less ownership

Funds ownership: 93.49% → 93.36% (-0.13%)

74% less call options, than puts

Call options by funds: $1.63M | Put options by funds: $6.25M

Holders
154
Holders Change
+3
Holders Change %
+1.99%
% of All Funds
2.65%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.16%
New
26
Increased
59
Reduced
41
Closed
23
Calls
$1.63M
Puts
$6.25M
Net Calls
-$4.62M
Net Calls Change
-$1.6M

Top Buyers

1
Marshall Wace
Marshall Wace
United Kingdom
+$29.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$26.6M
3
RG
Redmile Group
California
+$26.3M
4
LGM
Logos Global Management
California
+$18M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$16.8M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$30.2M
2
BI
BVF Inc
California
-$25.1M
3
Citadel Advisors
Citadel Advisors
Florida
-$18.2M
4
APM
Avidity Partners Management
Texas
-$13.7M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$10.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$177M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$169M +$3.5M +97,391 +2%
DCM
3
Driehaus Capital Management
Illinois
$163M +$4.06M +112,982 +3%
Marshall Wace
4
Marshall Wace
United Kingdom
$101M +$29.5M +820,723 +41%
RG
5
Redmile Group
California
$85.6M +$26.3M +731,270 +45%
PAMS
6
Pictet Asset Management (Switzerland)
Switzerland
$82.6M +$16.8M +467,889 +26%
Capital World Investors
7
Capital World Investors
California
$82.1M – – –
PA
8
Perceptive Advisors
New York
$76.6M – – –
Lord, Abbett & Co
9
Lord, Abbett & Co
New Jersey
$69.1M +$2.02M +56,265 +3%
Holocene Advisors
10
Holocene Advisors
New York
$66M – – –
Capital International Investors
11
Capital International Investors
California
$59.3M +$2.16M +60,000 +4%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$59.2M +$26.6M +738,566 +82%
CC
13
Commodore Capital
New York
$57.6M – – –
SC
14
Samlyn Capital
New York
$46.5M +$6.21M +172,797 +15%
RSCM
15
Rock Springs Capital Management
Maryland
$41.7M +$1.16M +32,357 +3%
Citadel Advisors
16
Citadel Advisors
Florida
$41.2M -$18.2M -506,037 -31%
BlackRock
17
BlackRock
New York
$37.6M +$6.26M +174,239 +20%
BI
18
BVF Inc
California
$32.5M -$25.1M -696,871 -44%
GPP
19
Great Point Partners
Connecticut
$30.7M -$9.14M -254,334 -23%
CS
20
Candriam SCA
Luxembourg
$27.5M -$3.68M -102,256 -12%
BBA
21
Baker Bros. Advisors
New York
$27.1M – – –
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$24.4M +$1.62M +45,000 +7%
EAM
23
Eventide Asset Management
Massachusetts
$23.1M +$6.17M +171,500 +37%
BC
24
Boxer Capital
California
$21.7M – – –
Millennium Management
25
Millennium Management
New York
$20.2M +$2.43M +67,658 +14%
1
2 3 4 5

XENE Hedge Fund Activity: Q3 2022 in Review

154 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2022, worth a combined $1.96B — up 21% from $1.62B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new XENE positions and 23 closed out — a net gain of 3 holders — while 59 added to existing stakes and 41 trimmed.

The largest buyer was Marshall Wace, adding an estimated $29.5M. The largest seller was Morgan Stanley, cutting an estimated $30.2M.

  • 154 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2022, up from 151 in Q2 2022.
  • Funds reported $1.96B of Xenon Pharmaceuticals stock for Q3 2022, up 21% quarter-over-quarter.
  • 26 funds opened new Xenon Pharmaceuticals positions in Q3 2022 and 23 closed out, a net change of +3 holders.
  • The largest Xenon Pharmaceuticals buyer in Q3 2022 was Marshall Wace, an estimated $29.5M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $30.2M sold.

Based on aggregated 13F filings for Q3 2022.